Hypereosinophilic Syndromes – Recent Advances In Definition

M K pag 153M K pag 153HYPEREOSINOPHILIC SYNDROMES – RECENT ADVANCES IN DEFINITION, CLASSIFICATION AND THERAPEUTIC APPROACH11. Gotlib J, Cross NC, Gilliland DG –Eosinophilic disorders: molecularpathogenesis, new classification, andmodern therapy. Best Pract Res ClinHaematol 2006; 19(3):535-56912. World Health Organisation –Classification of tumours ofhaematopoietic and lymphoid tissues,200813. Cools J, Stover EH, Gilliland DG –Detection of the FIP1L1-PDGFRAfusion in idiopathic hypereosinophilicsyndrome and chronic eosinophilicleukemia. Methods Mol Med 2006;125:177-18714. Cools J, Stover EH, Wlodarska I, etal – The FIP1L1-PDGFRalpha kinasein hypereosinophilic syndrome andchronic eosinophilic leukemia. CurrOpin Hemato 2004 Jan; 11(1):51-5715. Fletcher S, Bain B – EosinophilicLeukemia. British Medical Bulletin2007; 81,82:115-12716. Peros-Golubiciæ T, Smojver-Jezek S– Hypereosinophilic syndrome:diagnosis and treatment. Curr OpinPulm Med 2007 Sep; 13(5):422-42717. Reiter A, Grimwade D, Nicholas CPCross – Diagnosis and therapeuticmanagement of eosinophilia associatedchronic myeloproliferativedisorders. Haematologica 2007;92(09):1153-115718. Tefferi A – Modern diagnosis andtreatment of primary eosinophilia.Acta Haematol 2005; 114(1):52-6019. Baccarani M, Cilloni D, Rondoni M,et al – The efficacy of imatinibmesylate in patients with FIP1L1-PDGFRalpha-positivehypereosinophilic syndrome. Resultsof a multicenter prospective study.Haematologica 2007 Sep; 92(9):1173-1179. Epub 2007 Aug 1.20. Jovanovic JV, Score J, Waghorn K, etal – Low-dose imatinib mesylateleads to rapid induction of majormolecular responses and achievementof complete molecular remission inFIP1L1-PDGFRA-positive chroniceosinophilic leukemia. Blood 2007 Jun1; 109(11):4635-4640Mædica A Journal of Clinical Medicine, Volume 4 No.2 2009 153